Hemophilia B, a genetic bleeding disorder caused by deficient factor IX activity, has traditionally required lifelong prophylactic intravenous infusions. Etranacogene dezaparvovec, a gene therapy comprising an adeno-associated virus serotype 5 (AAV5) vector and the highly active Padua variant of factor IX, aims to provide a durable, single-dose solution that restores endogenous factor IX production and reduces bleeding episodes. Initial analyses had already demonstrated reductions in bleeding rates and low-grade adverse events; the final five-year data now confirm the long-term benefits and safety of this approach.
The HOPE-B trial enrolled adult men with severe hemophilia B (factor IX activity ≤2 IU/dL) who completed a lead-in period of at least six months on standard factor IX prophylaxis. Participants received a single intravenous infusion of etranacogene dezaparvovec regardless of preexisting neutralizing antibodies to AAV5. Over the five-year follow-up, researchers monitored annualized bleeding rates, factor IX activity, and safety outcomes.
The findings were as follows:
- Among 54 participants, the mean annualized bleeding rate decreased from 4.16 during the lead-in period to 1.52 during months 7–60 after infusion, a 63% reduction.
- Endogenous factor IX levels remained stable over five years, with a mean activity of 36.1 ± 15.7 IU/dL at year five.
- Annual factor IX use for prophylaxis and bleeding treatment dropped by 96%, from 257,339 IU per year before therapy to 10,924 IU per year post-treatment.
- Treatment efficacy was comparable in patients with or without preexisting AAV5 neutralizing antibodies, suggesting baseline immunity did not impact outcomes.
- Adverse events possibly related to therapy were rare after the first six months, with no new safety concerns observed during long-term follow-up.
The five-year data from the HOPE-B trial highlight the potential of etranacogene dezaparvovec to transform hemophilia B management. A single infusion can provide durable factor IX expression, substantially reduce bleeding episodes, and minimize reliance on regular factor replacement therapy. These findings underscore the promise of gene therapy as a long-term, effective treatment option for patients with hemophilia B.
"While these results are encouraging, ongoing monitoring and larger post-marketing studies will be essential to further assess long-term safety, durability of response, and the therapy’s impact on quality of life. Nonetheless, the HOPE-B trial provides compelling evidence that etranacogene dezaparvovec may redefine standard care for hemophilia B patients worldwide," the authors concluded.
Reference:
DOI: 10.1056/NEJMoa2514332
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.